Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second- or later-line GCD versus GCS therapy for advanced biliary tract cancer
jRCT1041230014Phase 2Active, not recruiting
- Start
- May 2023
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine, cisplatin, durvalumab and tegafur in biliary cancer (2 arms). Primary endpoint: Progression-free survival. Started May 2023; status: active, not recruiting.
02
Drugs
gemcitabinecisplatindurvalumabtegafur
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCT1041230014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041230014.